Quantcast
Last updated on April 23, 2014 at 17:08 EDT

Latest Eculizumab Stories

2014-04-03 08:29:04

-- Phase 2 Clinical Trial Planned to Begin This Quarter -- SEATTLE, April 3, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement?mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2),...

2014-03-10 08:29:22

- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE, March 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA)....

2013-11-10 00:21:29

- New Data from the Largest Prospective Trial of Adult Patients with aHUS and First Prospective Trial in Pediatric Patients with aHUS Confirm the Safety and Efficacy Profile of Soliris -- - ASN Meeting Also Features Three-year Update Data Highlighting Long-term Benefits of Chronic Soliris Therapy in Patients with aHUS - CHESHIRE, CT, Nov. 9, 2013 /CNW/ - Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from four clinical trials, all...

2013-10-23 08:30:04

NEW YORK, October 23, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), pSivida Corp. (NASDAQ: PSDV), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA) and Impax Laboratories Inc. (NASDAQ: IPXL). Today's readers may access these reports free of charge - including full...

2013-09-09 12:27:47

Novel Humanized Antibody Approach May Lead to Safer, More Cost Effective Treatment CLEVELAND, Sept. 9, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics (www.novelmed.com) announced the receipt of a combined $1.43 million SBIR Grant from the NIH. The first installment of the award (for $542,572) will be used to evaluate NovelMed's lead candidate's therapeutic superiority for treating Paroxysmal Nocturnal Hemoglobinuria (PNH). Subsequent funding, to be released on demonstration...

2013-07-25 12:26:35

DUBLIN, July 25, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6r3vhf/acquired_orphan) has announced the addition of the "Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential" [http://www.researchandmarkets.com/research/6r3vhf/acquired_orphan ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2011-02-28 04:59:00

Canadian Association of PNH Patients raises the volume on plea for access to life-saving treatment To view the Social Media Release, click here: http://smr.newswire.ca/en/canadian-association-of-pnh-patients/patients-with-rare-blood-disease-turn-to-social-media TORONTO, Feb. 28 /PRNewswire/ - With so few people affected by rare diseases, how does a group of less than 90 patients across Canada make their voices heardon a life-and-death issue such as access to treatment? Barry...

2009-01-05 05:30:00

Alexion Licenses PDL's Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (Nasdaq: PDLI) and Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today jointly announced that the companies have entered into a definitive license agreement and settlement agreement that resolve the legal disputes between them relating to Alexion's humanized antibody, Soliris(R) (eculizumab) and PDL's patents known as the Queen et al....

2008-12-09 06:00:00

CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), was observed by investigators to reduce blood measures associated with undiagnosed blood clots and inflammation in patients with PNH. A separate study found that Soliris was observed to reduce indicators of pulmonary artery hypertension (PAH) in patients with paroxysmal nocturnal hemoglobinuria (PNH), according to a new...

2008-12-08 12:30:00

CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P<0.001). Key secondary endpoints including fatigue (P<0.001) and transfusions/anemia...